Show simple item record

dc.contributor.authorChang, Hung
dc.contributor.authorChuang, Wen-Yu
dc.contributor.authorSun, Chien-Feng
dc.contributor.authorBarnard, Marc R.
dc.date2022-08-11T08:09:40.000
dc.date.accessioned2022-08-23T16:39:42Z
dc.date.available2022-08-23T16:39:42Z
dc.date.issued2012-02-22
dc.date.submitted2012-08-27
dc.identifier.citationDiagn Pathol. 2012 Feb 22;7:19. <a href="http://dx.doi.org/10.1186/1746-1596-7-19" target="_blank">Link to article on publisher's site</a> 2012 Chang et al; licensee BioMed Central Ltd.
dc.identifier.issn1746-1596 (Linking)
dc.identifier.doi10.1186/1746-1596-7-19
dc.identifier.pmid22356850
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39531
dc.description.abstractConcurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia (AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12)(q33;p13), which indicated presence of PDGFRB gene translocations. Therefore, this disease belongs to the new WHO category of myeloid and lymphoid neoplasms with abnormalities in PDGFRA, PDGFRB and FGFR1 genes. Although such genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML and T lymphoblastic lymphoma involving PDGFRB mutations. The patient was treated with cytarabine and daunomycin in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection. Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22356850&dopt=Abstract">Link to Article in PubMed</a>
dc.rights© 2012 Chang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.subjectAdult
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCombined Modality Therapy
dc.subjectCytarabine
dc.subjectDaunorubicin
dc.subjectFatal Outcome
dc.subjectGraft vs Host Disease
dc.subjectHumans
dc.subjectLeukemia, Myeloid, Acute
dc.subjectMale
dc.subjectNeoplasms, Multiple Primary
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subjectReceptor, Platelet-Derived Growth Factor beta
dc.subjectStem Cell Transplantation
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.subjectPathology
dc.titleConcurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes
dc.typeJournal Article
dc.source.journaltitleDiagnostic pathology
dc.source.volume7
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=3325&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2325
dc.identifier.contextkey3266175
refterms.dateFOA2022-08-23T16:39:42Z
html.description.abstract<p>Concurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia (AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12)(q33;p13), which indicated presence of PDGFRB gene translocations. Therefore, this disease belongs to the new WHO category of myeloid and lymphoid neoplasms with abnormalities in PDGFRA, PDGFRB and FGFR1 genes. Although such genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML and T lymphoblastic lymphoma involving PDGFRB mutations. The patient was treated with cytarabine and daunomycin in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection. Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.</p>
dc.identifier.submissionpathoapubs/2325
dc.contributor.departmentDepartment of Medicine
dc.source.pages19


Files in this item

Thumbnail
Name:
1746_1596_7_19.pdf
Size:
1.147Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record